|Articles|June 17, 2015

Quintiles Introduces Infosario One Mobile App

Author(s)Applied Clinical Trials Editorial Staff

Quintiles is extending its award-winning Quintiles Infosario® technology platform with mobile access to clinical trial information.

Quintiles is extending its award-winning Quintiles Infosario^® technology platform with mobile access to clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones. One mobile app can be personalized with different filters so users can quickly see precisely what’s most important to them. These customized views are then served up in mobile-friendly charts that automatically reflect the latest information.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© putilov_denis - © putilov_denis - stock.adobe.com

October 28th, 2026

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.

October 28th, 2026

What It Would Take to Make Community Trials Accessible and Scalable

In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.

October 28th, 2026

ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention

In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure

October 27th, 2026

Closing the Medical Writing Capacity Gap: Why Training Beats Technology

Medical writing capacity pressure is fundamentally a talent development problem, not a technology problem, since hybrid resourcing and AI cannot substitute for the experienced judgment needed to review AI output and mentor the next generation of writers.

October 27th, 2026

Why Legacy Trial Workflows Weigh So Heavily on Community and Rural Clinics

In this video interview, Kent Thoelke, CEO of Paradigm Health, describes how manual eligibility screening and swivel-chair data entry force community sites to trade billable patient care for research, and why that burden is so hard to absorb.

October 27th, 2026

ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval

In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.

October 26th, 2026

How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.

© FlowStudio - © FlowStudio - stock.adobe.com

October 26th, 2026

Measuring What Matters: Realigning Clinical Endpoints with Patient Reality

Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restraint.